Results 261 to 270 of about 516,295 (311)

Recombinant Protein Based Therapeutics for IPF

Inflammation & Allergy-Drug Targets, 2013
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, irreversible, and usually fatal interstitial lung disease of unknown cause [1, 2]. The aetiology of IPF is unknown, although identified risk factors for IPF include cigarette smoking, environmental exposures, microbial agents, age, male gender and gastroesophageal reflux disease (GERD ...
Joseph M, Parker, Michael S, Kramer, Lynne A, Murray   +2 more
openaire   +2 more sources

Recombinant protein expression for therapeutic applications

Current Opinion in Biotechnology, 2002
In recent years, the number of recombinant proteins used for therapeutic applications has increased dramatically. Many of these applications involve complex glycoproteins and antibodies with relatively high production needs. These demands have driven the development of a variety of improvements in protein expression technology, particularly involving ...
Dana C, Andersen, Lynne, Krummen
openaire   +2 more sources

Induction of Tolerance to Recombinant Therapeutic Proteins

Journal of Interferon & Cytokine Research, 2001
The specific IgM and IgG antibody responses to subcutaneous (s.c.) treatment of mice with recombinant human IFN-alpha2a (rHuIFN-alpha2a) or IFN-beta were inhibited in a dose-dependent manner by prior oromucosal (o.m.) administration of rHuIFN-alpha2a or IFN-beta, respectively. Pretreatment of animals once a day for 7 days by the o.m.
J F, Meritet, C, Maury, M G, Tovey
openaire   +2 more sources

Glycosylation control technologies for recombinant therapeutic proteins

Applied Microbiology and Biotechnology, 2018
Protein glycosylation is a very important quality attribute of any biopharmaceutical product as it affects the efficacy, serum half-life, and antigenicity of a molecule. The present expression hosts commercially utilized for a recombinant glycoprotein production generally cannot produce a desired and uniform glycan composition and generally exhibit non-
Sanjeev K. Gupta, Pratyoosh Shukla
openaire   +2 more sources

Integrated continuous production of recombinant therapeutic proteins

Biotechnology and Bioengineering, 2012
AbstractIn the current environment of diverse product pipelines, rapidly fluctuating market demands and growing competition from biosimilars, biotechnology companies are increasingly driven to develop innovative solutions for highly flexible and cost‐effective manufacturing.
Veena, Warikoo, Rahul, Godawat, Kevin, Brower, Sujit, Jain, Daniel, Cummings, Elizabeth, Simons, Timothy, Johnson, Jason, Walther, Marcella, Yu, Benjamin, Wright, Jean, McLarty, Kenneth P, Karey, Chris, Hwang, Weichang, Zhou, Frank, Riske, Konstantin, Konstantinov   +15 more
openaire   +2 more sources

Manufacturing of recombinant therapeutic proteins in microbial systems

Biotechnology Journal, 2006
AbstractRecombinant therapeutic proteins have gained enormous importance for clinical applications. The first recombinant products have been produced in E. coli more than 20 years ago. Although with the advent of antibody‐based therapeutics mammalian expression systems have experienced a major boost, microbial expression systems continue to be widely ...
Klaus, Graumann, Andreas, Premstaller
openaire   +2 more sources

Structural Characterization of Recombinant Therapeutic Proteins by Circular Dichroism

Current Pharmaceutical Biotechnology, 2011
Most of the protein therapeutics are now produced by recombinant DNA technology. The advantages of recombinant proteins are related to their higher specificity and to their safety as exposure to animal or human diseases. However, several problems are still present in development of recombinant proteins as therapeutics, such as low bioavailability ...
BERTUCCI, CARLO, PISTOLOZZI, MARCO, DE SIMONE, ANGELA   +2 more
openaire   +4 more sources

Potential therapeutic recombinant proteins comprised of peptides containing recombined T cell epitopes

Molecular Immunology, 1994
The complete primary structure of Fel d I2 has been determined and shown to be comprised of two separate polypeptide chains (designated chain 1 and 2). Overlapping peptides covering the entire sequence of both chains of Fel d I have been used to map the major areas of human T cell reactivity.
Bruce L. Rogers, Julian F. Bond, Sandra J. Craig, Anneliese K. Nault, Debra B. Segal, Jay P. Morgenstern, Chen Meei-Song, Christine B. Bizinkauskas, Catherine M. Counsell, Annette M. Lussier, Thomas Luby, Kuo Mei-Chang, Thomas J. Briner, Richard D. Garman   +13 more
openaire   +2 more sources

Current views on N-glycolylneuraminic acid in therapeutic recombinant proteins

Trends in Pharmacological Sciences, 2021
The incorporation of the non-human N-glycolylneuraminic acid (Neu5Gc) in therapeutic recombinant proteins raises clinical concerns due to its immunogenic potential and the high prevalence of pre-existing anti-Neu5Gc antibodies in humans. The scientific literature is ambiguous regarding the actual impact of Neu5Gc-containing biotherapeutics as no severe
Renato Mastrangeli, Maria Concetta Audino, Wolf Palinsky, Hervé Broly, Horst Bierau   +4 more
openaire   +2 more sources

Recombinant therapeutic proteins: Production platforms and challenges

Biotechnology Journal, 2008
AbstractSince the approval of insulin in 1982, more than 120 recombinant drug substances have been approved and become available as extremely valuable therapeutic options. Exact copying of the most common human form is no longer a value per se, as challenges, primarily related to the pharmacokinetics of artificial recombinant drugs, can be overcome by ...
openaire   +2 more sources